Zimmer, US medical device maker, is set to secure conditional approval from European Union regulators for its proposed $13.4 billion takeover of rival Biomet, Reuters reported on Wednesday.
Zimmer, which would become the No. 2 player in the $45 billion global orthopaedics market after the acquisition, revised its concessions to the European Commission last month, saying they were generally consistent with an earlier package.
In December the company proposed selling one brand for partial, or unicompartmental, knee replacements and one elbow brand in Europe, as well as a knee replacement brand in two European countries.
The EU competition authority has set a May 26 deadline for its decision.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI